Study of PROSPECT IV (Prostamol: Perspectives of Combined Therapy) in Patients with Benign Prostatic Hyperplasia

The study aimed to evaluate the efficacy and safety of a nine-year combination therapy using "Flosin – Prostamol Uno" in patients with benign prostatic hyperplasia (BPH). Out of 94 patients from the previous PROSPECT III study, 37 were followed up for 9 years. The study compared two groups: 33 patients received "Flosin – Prostamol Uno," and 4 received "doxazosin – finasteride." Results indicated that "Flosin – Prostamol Uno" was highly effective and well-tolerated, with a lower incidence of adverse events (5.75%) compared to the control group (27%). The level of acute urinary retention in the treatment group was 19%. The study concluded that patient adherence to the "Flosin – Prostamol Uno" therapy was high, and it effectively reduced the risk of acute urinary retention.